Novo Nordisk has released promising data showing that people who switched from obesity injections, including its own Wegovy shot and Eli Lilly's rival Zepbound injection, to Novo’s newly available Wegovy pill continued to lose weight over a three-month period. This analysis, based on real-world data from Ro’s telehealth platform involving 194 overweight or obese patients, found that those who remained on the oral treatment lost about 4% of their body weight, or roughly 8.8 pounds on average, from a starting weight of 221 pounds. Nearly 40% of participants achieved at least 5% weight loss after switching to the pill.

The results suggest that patients might not need to adhere to weekly injectable treatments indefinitely and could instead transition to the more convenient oral option with comparable or even enhanced weight loss benefits. Novo's chief scientific officer, Martin Holst Lange, highlighted that the pill offers the same safety and tolerability as the injections but with added convenience, which many patients desire. Patient feedback reinforced this preference, with 75% expressing satisfaction with the switch, and many reported improvements such as healthier eating habits and better-fitting clothes.

Despite the encouraging findings, Novo acknowledged the inherent limitations of real-world studies, such as incomplete data, self-reporting biases, and the inability to generalize results broadly. Still, the collaboration with Ro emphasizes the importance of harnessing patient data to personalize healthcare, focusing on understanding individual responses to obesity treatments and optimizing dosing schedules to enhance long-term outcomes.

In addition to the Wegovy pill data, Novo also revealed early results from its experimental obesity drug CagriSema, a combination therapy involving semaglutide and cagrilintide. This drug showed promise in reducing cravings for high-calorie foods and improving organ and bone health in patients with obesity or type 2 diabetes during a yearlong brain imaging study. CagriSema is expected to launch early next year, with further advanced formulations in development, marking a significant advance in Novo’s obesity and diabetes pipeline.